Opthea Limited

ASX:OPT.AX

0.63 (AUD) • At close May 22, 2024
Bedrijfsnaam Opthea Limited
Symbool OPT.AX
Munteenheid AUD
Prijs 0.64
Beurswaarde 424,197,760
Dividendpercentage 0%
52-weken bereik 0.313 - 0.815
Industrie Biotechnology
Sector Healthcare
CEO Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.
Website https://opthea.com

An error occurred while fetching data.

Over Opthea Limited

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel

Vergelijkbare Aandelen

Neuren Pharmaceuticals Limited logo

Neuren Pharmaceuticals Limited

NEU.AX

20.71 AUD

Monash IVF Group Limited logo

Monash IVF Group Limited

MVF.AX

1.46 AUD

AFT Pharmaceuticals Limited logo

AFT Pharmaceuticals Limited

AFP.AX

3.2 AUD

Sigma Healthcare Limited logo

Sigma Healthcare Limited

SIG.AX

1.25 AUD

Incannex Healthcare Limited logo

Incannex Healthcare Limited

IHL.AX

0.041 AUD

Mayne Pharma Group Limited logo

Mayne Pharma Group Limited

MYX.AX

5.34 AUD

Trajan Group Holdings Limited logo

Trajan Group Holdings Limited

TRJ.AX

1 AUD

Capitol Health Limited logo

Capitol Health Limited

CAJ.AX

0.25 AUD

Immutep Limited logo

Immutep Limited

IMM.AX

0.475 AUD

Financiële Gegevens

Cijfers zijn in miljoenen (AUD)

Cijfers zijn in miljoenen (AUD)